Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

Kenvue (KVUE), the company behind Tylenol and Neutrogena, announced that Thibaut Mongon had left the company, naming Kirk ...

KENVUE Hedge Fund Activity. We have seen 533 institutional investors add shares of KENVUE stock to their portfolio, and 492 decrease their positions in their most recent quarter.

View the latest Kenvue Inc. (1KVUE) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Shares of Kenvue Inc. KVUE advanced 1.53% to $23.96 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.63% to 5,604.14 ...

Shares of Kenvue Inc. KVUE shed 2.08% to $23.50 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the Dow Jones Industrial Average DJIA remaining ...

Kenvue's KVUE short percent of float has risen 61.49% since its last report. The company recently reported that it has 40.73 million shares sold short , which is 2.81% of all regular shares that ...

Kenvue (KVUE) stock spikes as activist investor Third Point Capital takes a stake, sparking renewed scrutiny on the J&J (JNJ) spinoff. Read more here.

Kenvue Inc. KVUE operates as a consumer health company in the U.S. and internationally. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The 52-week ...

In the first half of fiscal 2025, the company generated a staggering $9.42 billion in free cash flow, which supported stock repurchases of $8.41 billion and $2.33 billion in dividends.